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Abstract
Background: The optimal sequencing of chemotherapy and radiotherapy after breast surgery was
largely studied but remains controversial. Concurrent chemo-radiotherapy is a valuable method for
adjuvant treatment of breast cancer which is under ongoing research program in our hospital. We
are evaluating the feasibility of the concomitant use of chemotherapy retrospectively.
Methods:  Two hundred forty four women having breast cancer were investigated in a
retrospective study. All patients were either treated by radical surgery or breast conservative
surgery. The study compares two adjuvant treatments associating concomitant chemotherapy and
radiotherapy. In the first group (group A) the patients were treated by chemotherapy and
radiotherapy in concomitant way using anthracycline (n = 110). In the second group (group B) the
patients were treated by chemotherapy and radiotherapy in concomitant way using CMF treatment
(n = 134). Chemotherapy was administered in six cycles, one each 3 weeks. Radiotherapy delivered
a radiation dose of 50 Gy on the whole breast (or on the external wall) and/or on the lymphatic
region. The Kaplan-Meier method was used to estimate the rates of disease free survival, loco-
regional recurrence-free survival and overall survival. The Pearson Khi2 test was used to analyse
the homogeneity between the two groups. The log-rank test was used to evaluate the differences
between the two groups A and B.
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Results: After 76.4 months median follow-up (65.3 months mean follow up), only one patient
relapsed to loco-regional breast cancer when the treatment was based on anthracycline. However,
8 patients relapsed to loco-regional breast cancer when the treatment was based on CMF. In the
anthracycline group, the disease free survival after 5 years, was 80.4% compared to 76.4% in the
CMF group (Log-rank test: p = 0.136). The overall survival after 5 years was 82.5% and 81.1% in
the anthracycline and CMF groups respectively (Log-rank test: p = 0.428). The loco-regional free
survival at 5 years was equal to 98.6% in group A and 94% in group B (Log-rank test: p = 0,033).
The rate of grade II and grade III anaemia was 13.9% and 6.7% in anthracycline group and CMF
group respectively (Khi2-test: p = 0.009). The rate of grade II and grade III skin dermatitis toxicity
was 4.5% in the group A and 0% in the group B (Khi2-test: p = 0.013).
Conclusion: From the 5 years retrospective investigation we showed similar disease free survival
and overall survival in the two concurrent chemo-radiotherapy treatments based on anthracycline
and CMF. However in the loco-regional breast cancer the treatment based on anthracycline was
significantly better than that of the treatment based on CMF. There was more haematological and
skin dermatitis toxicity in the anthracycline group.
Background
In the case of early breast cancer and after radical mastec-
tomy or conservative surgery, adjuvant radiotherapy is
mandatory for diminishing the risk of recurrence [1-9].
Adjuvant chemotherapy is equally mandatory for dimin-
ishing metastasis recurrences [10-12]. However, the opti-
mal sequence of treatments is not clearly defined and
remains controversial. Several trials have shown that the
incidence of spared metastasis is more important in the
case of delay of chemotherapy, and local's recurrences are
more frequents in the case of delay of radiotherapy
[13,14]. Current standard treatment sequence is chemo-
therapy followed by radiotherapy. We are trying by this
retrospective study to document and support the feasibil-
ity and efficiency of concurrent chemo-radiotherapy.
Methods
Patient selection
From January 2001 to December 2002, a large group of
244 patients with early breast carcinoma were selected at
the National Institute of Oncology in Rabat, for investiga-
tion during treatment and up to now follow up. The
patients were divided in two groups on the basis of chem-
otherapy treatment. In group A the treatment was based
on anthracycline and in group B the treatment was based
on CMF. Eighty four percent of the investigated cases
(81% in group A and 86.5% in group B; Pearson-Khi2 test:
p = 0.23) had radical surgery [201 received Patey mastec-
tomy and 4 received Halsted mastectomy (2 in group A
and 2 in group B)] and the remaining 16% of the cases
(19% in group A and 13.5% in group B; Pearson-Khi2 test:
p  = 0.23) had breast conservative surgery [34 received
tumorectomy and 5 received quadrentectomy (3 in group
A and 2 in group B)]. All the 244 patients underwent con-
current adjuvant chemo-radiotherapy. In the concurrent
chemo-radiotherapy both chemotherapy and radiother-
apy were delivered at the same time. The median number
of chemotherapy cycles delivered with radiotherapy was 2
(ranging from 1 to 5). Eighty percent of the patients (195
patients) received 2 or more chemotherapy cycles with
concomitant radiotherapy. Patient medical records were
retrospectively analysed and the following parameters
were considered: demographic data, clinical stages, histo-
logical findings, treatment and outcome. Radiological,
pathological and surgical reports were reviewed to deter-
mine the stage of the disease at the time of surgery by
using the 2002 TNM classification for breast cancer [15].
The diagnostic instrumental examinations used to stage
patients were: chest radiograph performed in all patients;
abdominal ultrasound performed in all patients; and
bone scan performed in only 16% of the patients (39
patients).
Treatment plan
Data about treatment, notably surgery, chemotherapy and
radiotherapy, were extracted from patient medical
records. The date and site of recurrence and, if applicable,
the date of death were also considered. The first group A
of 110 patients was treated with anthracycline based pro-
tocol and the second group B of 134 patients was treated
with CMF protocol. Additional file 1 and Diagram 1 sum-
marizes the therapeutic strategy. According to the protocol
followed at our institute, 95.5% of the patients received a
radiotherapy treatment delivered to the whole breast or to
thoracic wall (99.1% in group A and 92.5% in group B);
in addition, the same 95.5% of the patients received a
radiotherapy treatment delivered to the regional lymph
nodes. The 4.5% of patients left received a radiotherapy
treatment delivered to the whole breast or to the thoracic
wall, in addition to a radiotherapy treatment delivered in
the regional lymph nodes. All patients were treated with
external beam radiotherapy using tangential fields of Co-
60-gamma-Ray. The total delivered dose was 50 Gy,
divided as 2-Gy daily fractions. The complementary treat-Radiation Oncology 2009, 4:12 http://www.ro-journal.com/content/4/1/12
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ment was given by electrons or by breast brachytherapy.
The total complementary dose ranged from 10 to 20 Gy
for 10 patients. Chemotherapy consisted of: a- intrave-
nous CMF (cyclophosphamide 500 mg/m2, methotrexate
60 mg/m2, and 5-fluorouracil 500 mg/m2) on day 1,
repeated every 21 days for six courses for 134 patients, b-
intravenous AC60 (doxorubicin 60 mg/m2  and cyclo-
phosphamide 600 mg/m2) on day 1, repeated every 21
days for six courses for 57 patients, c- intravenous FEC75
(5-fluorouracile 500 mg/m2, epirubicin 75 mg/m2, and
cyclophosphamide 500 mg/m2) on day 1, repeated every
21 days for six courses for 23 patients and d- intravenous
FAC50 (5-fluorouracile 500 mg/m2, doxorubicin 50 mg/
m2, and cyclophosphamide 500 mg/m2) on day 1,
repeated every 21 days for six courses for 20 patients, and
e- sequential treatment, repeated every 21 days for six
courses for 10 patients (table 1, additional file 1 and dia-
gram 1). We retrospectively compared toxicity, disease
free survival and overall survival between two therapeutic
groups A and B and between the sub-groups within A and
B.
Statistical analysis
Overall survival (OS) and disease free survival (DFS) were
analyzed statistically in all patients. Time to recurrence
was calculated from the date of surgery to the date of first
documented relapse or to the date of last follow up. Over-
all survival was calculated from the date of histological
diagnosis (Fine Needle Aspiration, biopsy, or surgery) to
the date of death or to the date of last follow up. The Kap-
lan-Meier method was used to estimate the rates of DFS,
loco-regional recurrence-free survival (LRFS) and OS. The
log-rank test was used to evaluate the differences between
the two groups A and B. The distribution homogeneity
was analyzed with the Pearson chi2-test for both groups
and for all subgroups. The distribution of patient charac-
teristics was partly imbalanced. The influence on survival
of several prognostic factors (age, lymph node involve-
ment, tumour volume, tumour grade, receptor status, and
treatment regime) was analyzed by Cox regression. Statis-
tical evaluation was carried out using SPSS 13.0 statistical
software.
Results
Patient characteristics
Between January 2001 and December 2002, 244 women
were retrospectively evaluated. One hundred ten patients
received concurrent chemo-radiotherapy with anthracy-
cline based regimen and 134 patients received concurrent
chemo-radiotherapy with CMF based regimen. The demo-
graphic, clinical, pathologic, and therapeutic characteris-
tics of the two groups of patients were summarized in
table 2. After the analysis of homogeneity characteristics
of the two groups we found more women aged less than
40 years (Khi2-test: p = 0.039) and more lymph node
involvement (Khi2-test: p = 0.001) in the anthracycline
group than in group B (table 2). The progesterone recep-
tor status was the only statistically different subgroup
from the three most important anthracycline sub-groups
(Table 3). The homogeneity between the groups of
patients managed either with mastectomy or breast con-
servative therapy (BCT) was also studied and summarized
in table 4. For all patients, the mean delay of chemother-
apy after surgery was 6.9 weeks (ranging from 0.7 to 37.9
weeks). And the mean delay of radiotherapy after surgery
was 12.4 weeks (ranging from 2.4 to 53.3 weeks). In the
two groups A and B respectively, 96.4% and 97.7% of the
patients received the 6 courses of chemotherapy. All
patients in the two groups received 100% of the planned
radiotherapy dose.
Treatment compliance
Analysis of haematological toxicity showed that the rate of
grade III-IV neutropenia was 9.3% vs 6.2% in group A and
B respectively (Khi2-test: p = 0.4). The rate of grade II-III
anaemia was 13.9% vs 6.7% in anthracycline group and
CMF group respectively (Khi2-test: p = 0.009) (Table 5).
There was no cardiac toxicity that was clinically detectable
in the two arms. The left ventricular fraction ejection
(LVFE) was evaluated in only 7 patients (2 patients in the
anthracycline group and 5 in the CMF group) and was
normal (LVFE ranged between 63% and 87%). This con-
stitutes the main limitation of our retrospective study. The
second limitation was the skin dermatitis toxicity events
which were noted in only few cases when the patients pre-
sented high toxicity grade. Therefore, we showed that
4.5% of the patients treated with anthracycline regimen
had poor cosmetic results (grade II-III skin dermatitis tox-
icity), but in no patient of the group B the skin dermatitis
toxicity was noted (Khi2-test: p = 0.013). The third limita-
tion was the lake of pulmonary toxicity follow up in our
Table 1: Sequential treatments
Protocol Number of patients
2AC60 → 4CMF* 2
2FAC50 → 4CMF* 1
6CMF* → 4AT 1
3FAC50 → 3CMF* 2
4CMF → 2FEC75* 1
2AC60 → 4CMF* 1
2CMF* → 4 AC 1
4AC* → 2CMF 1
* = regimen delivered in concomitant with radiotherapy; CMF = 
cyclophosphamide 500 mg/m2, methotrexate 60 mg/m2, and 5-
fluorouracil 500 mg/m2; AC60 = doxorubicin 60 mg and 
cyclophosphamide 600 mg/m2; FEC75 = -fluorouracile 500 mg/m2, 
epirubicin 75 mg/m2, and cyclophosphamide 500 mg/m2; FAC50 = 5-
fluorouracile 500 mg/m2, doxorubicin 50 mg/m2, and 
cyclophosphamide 500 mg/m2; AT = doxorubicin 50 mg/m2 and 
docetaxel 75 mg/m2Radiation Oncology 2009, 4:12 http://www.ro-journal.com/content/4/1/12
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Table 2: Demographic, clinical, histological, molecular and treatment characteristics of patients and analysis of groups homogeneity 
(test Pearson Khi2)
Characteristic Group A [n = 110] No (%) Group B [n = 134] No (%) p value
Age
<40 31 (28.2%) 23 (17.2%) 0.039
≥40 79 (71.8%) 111 (82.8%)
Menopausal status
No 75 (72.8%) 77 (62.1%) 0.087
Yes 28 (27.2%) 47 (37.9%)
Side
Right 48 (43.6%) 71 (53%) 0.146
Left 62 (56.4%) 63 (47%)
Surgery
Mastectomy (Patey or Halsted) 89 (80.9%) 116 (86.6%) 0.23
Conservative 21 (19.1%) 18 (13.4%)
Histology
DIC 99 (94,3%) 120 (90,9%) 0.33
LIC 6 (5.7%) 12 (9.1%)
SBR
I 6 (5.7%) 11 (8.5%) 0.567
II 69 (65.1%) 87 (66.9%)
III 31 (29.2%) 32 (24.6%)
Hormonal receptors
ER
Positive 77 (72%) 97 (73.5%) 0.793
Negative 30 (28%) 35 (26.5%)
PR
Positive 61 (57.5%) 82 (62.1%) 0.474
Negative 45 (42.5%) 50 (37.9%)
Tumour
pT1 16 (14.7%) 19 (14.5%) 0.732
pT2 62 (56.9%) 76 (58%)
pT3 28 (25.7%) 29 (22.1%)
pT4 3 (2.8%) 7 (5.3%)
pN, axillary
pN0 20 (18.2%) 40 (29.9%) 0.001
pN1 30 (27.3%) 42 (31.3%)
pN2 31 (28.2%) 42 (31.3%)
pN3 29 (26.4%) 10 (7.5%)
Breast/thoracic wall irradiation
Yes 109 (99.1%) 124 (92.5%) 0.014
No 1 (0.9%) 10 (7.5%)
Prophylactic supraclavicular fossa radiotherapy
Yes 104 (94.5%) 127 (94.8%) 0.936
No 6 (5.5%) 7 (5.2%)
Internal mammary radiotherapy
Yes 105 (95.5%) 128 (95.5%) 0.98
No 5 (4.5%) 6 (4.5%)Radiation Oncology 2009, 4:12 http://www.ro-journal.com/content/4/1/12
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data base. Nevertheless, only 2 patients in the AC60 sub-
groups showed dry cough.
Outcomes
After 76.4 months median follow-up and 65.3 months
mean follow up (ranging between 9.6 to 106 months),
only one patient developed loco-regional relapse when
the treatment was based on anthracycline. In contrast, 8
patients relapsed to loco- regional breast cancer in the
CMF group. The 5 years loco-regional recurrence free sur-
vival rate was equal to 98.6% in group A vs 94% in group
B; Log-rank test: p = 0.033 (Figure 1). The 5 years rate of
DFS was 80.4% in group A vs 76.4% in group B; Log-rank
test: p = 0.136 (Figure 2). The 5 years overall survival rate
was 82.5% in group A vs 81.1% in group B; Log-rank test:
p = 0.428 (Figure 3). Using univariate analysis, we found
that the only prognosis factor influencing survival was the
lymph node involvement status (p = 0.007) (Cox regres-
sion) (table 6).
Analysis of the data showed no difference in survival
between the 3 anthracycline cycles regimen: AC60, FEC75
and FAC 50; Log-rank test: p = 0.982 (Figure 4). And there
was no difference in disease free survival and overall sur-
vival between the patients treated by mastectomy or breast
conservative therapy (DFS: p = 0.288; OS: p = 0.173) (Fig-
ure 5 and 6).
Discussion
Radiotherapy and chemotherapy after surgery are manda-
tory in the multidisciplinary management of early-stage
breast cancer. Even if the optimal sequencing of theses
treatments was largely studied during the last two dec-
ades, they remain controversial. Several retrospective
studies have suggested an increase in local recurrence rates
when radiotherapy was delivered after the end of chemo-
therapy treatment [13,14]. Hartsell et al showed that
delays in the irradiation treatment were associated with
increased risk of relapse in the breast cancer and recom-
mended that radiotherapy treatment should be delivered
within 120 days after breast surgery. Other authors
showed that a delay in the initiation of RT for a period of
6 months or greater from diagnosis resulted in a higher
local failure rate with an increased rate of distant metas-
tases and a decreased overall survival rate. The Joint Cen-
tre for Radiation Therapy Trial (JCRT) confirmed theses
results (rate of local recurrences was 5% vs 14% when
radiotherapy was delayed) and suggested that radiother-
apy should be delivered before chemotherapy [16]. How-
ever, other retrospective studies have suggested an
increased rate of distant recurrences when RT was deliv-
ered before chemotherapy [17-20].
The current standard of care of early breast cancer was the
surgery followed by chemotherapy followed by radiother-
apy. Concurrent chemo-radiotherapy is a valuable
method because of two advantages: 1. delivering the
booths treatment in same time without any delay of
chemotherapy or radiotherapy; 2. adjunction of chemo-
therapy to radiotherapy might produce a biological syn-
ergy effect that can increase the efficacy of the treatment
[21]. Chemotherapy treatments based on liposomal dox-
orubicin, paclitaxel and vinorelbine, with concomitant RT
in non operable and recurrent disease, were found to be
of good efficacy and tolerability [21,22]. Reirradiation
with concomitant chemotherapy was shown to have pos-
itive effect [21,23].
The promising results of concurrent chemo-radiotherapy
showed in previous studies leaded us to investigate the
efficacy and tolerability of this treatment in early breast
cancer.
The objective of our contribution was to document and
support the feasibility of concomitant treatment used at
the national institute of oncology in Rabat and to con-
front our results to the results of 3 randomised studies
published previously. Our work concerned the study of a
data base of 244 patients treated by radical mastectomy
(84%) or by BCT (16%) to compare efficacy and tolerabil-
ity of two concomitant protocols: the first with anthracy-
cline based regimen and the second with CMF regimen.
After 76.4 months median follow-up and 65.3 months
mean follow up (ranging between 9.6 to 106 months) we
found no statistical difference in the DFS and the OS
between the two therapeutic groups A and B. 5 years rate
of DFS was 80.4% in group A vs 76.4% in group B; Log-
rank test: p = 0.136 and the 5 year overall survival rate was
82.5% in group A vs 81.1% in group B; Log-rank test: p =
0.428. However, to better explain these results and dem-
onstrate the beneficial effect of one of the two protocols
(anthracycline regimen and CMF regimen) over the other,
the homogeneity of two groups was analysed. This analy-
sis showed the presence of poorer prognosis factors in the
Axillary radiotherapy
Yes 18 (16.4%) 31 (23.1%) 0.189
No 92 (83.6%) 103 (76.9%)
SBR = Scarf-Bloom-Richardson; DIC = ductal invasive carcinoma; LIC = lobular invasive carcinoma; ER = estrogen receptor; PR = progesterone 
receptor
Table 2: Demographic, clinical, histological, molecular and treatment characteristics of patients and analysis of groups homogeneity 
(test Pearson Khi2) (Continued)Radiation Oncology 2009, 4:12 http://www.ro-journal.com/content/4/1/12
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anthracycline group (younger women and more lymph
node involvement). In fact, there were significantly
younger women (Pearson-Khi2 test: p = 0.039) and more
positive lymph nodes (Pearson-Khi2 test: p = 0.001) in the
anthracycline group. In addition, we showed significantly
better local control in the anthracycline group; Log-rank
test: p = 0.033. Overall, the patients in the two groups
showed a very good loco-regional control.
In Europe, three recent randomised phase III trials were
conducted to compare the sequential protocol (chemo-
therapy first) to the concomitant protocol: 1- in the first
Table 3: Analysis of anthracycline sub-groups (AC60, FEC75 and FAC50) homogeneity (test Pearson Khi2)
Patients characteristics Group FEC75 [n = 23] No (%) Group FAC50 [n = 20] No (%) Group AC60 [n = 57] No (%) p value
Age
<40 8 (34.8%) 7 (35%) 14 (24.6%) 0.53
≥40 15 (65.2%) 13 (65%) 43 (75.4%)
Menopausal status
No 20 (90.9%) 14 (77.8%) 35 (66%) 0.075
Yes 2 (9.1%) 4 (22.2%) 18 (34%)
Side
Right 14 (60.9%) 7 (35%) 24 (42.1%) 0.188
Left 9 (39.1%) 13 (65%) 33 (57.9%)
Surgery
Mastectomy 5 (21.7%) 5 (25%) 8 (14%) 0.457
Conservative 18 (78.3%) 15 (75%) 49 (86%)
Histology
CCI 20 (95.2%) 19 (95%) 52 (94.5%) 0.992
CLI 1 (4.8%) 1 (5%) 3 (5.5%)
SBR
I 0 1 (5%) 4 (7.1%) 0.31
II 14 (70%) 10 (50%) 39 (69.6%)
III 6 (30%) 9 (45%) 13 (23.2%)
Hormonal receptors
ER
Positive 18 (81.8%) 11 (55%) 42 (76.4%) 0.106
Negative 4 (18.2%) 9 (45%) 13 (23.6%)
PR
Positive 17 (77.3%) 7 (35%) 31 (57.4%) 0.022
Negative 5 (22.7%) 13 (65%) 23 (42.6%)
Tumour
pT1 6 (26.1%) 1 (5%) 9 (16.1%) 0.514
pT2 10 (43.5%) 13 (65%) 32 (57.1%)
pT3 7 (30.4%) 5 (25%) 13 (23.2%)
pT4 0 1 (5%) 2 (3.6%)
pN, axillary
pN0 6 (26.1%) 3 (15%) 9 (15.8%) 0.807
pN1 4 (17.4%) 4 (20%) 15 (26.3%)
pN2 7 (30.4%) 5 (25%) 18 (31.6%%)
pN3 6 (26.1%) 8 (40%) 15 (26.3%%)
FEC75 = 5-fluorouracile 500 mg/m2, epirubicin 75 mg/m2, and cyclophosphamide 500 mg/m2; FAC50 = 5-fluorouracile 500 mg/m2, doxorubicin 50 
mg/m2, and cyclophosphamide 500 mg/m2; AC60 = doxorubicin 60 mg and cyclophosphamide 600 mg/m2 ; SBR = Scarf-Bloom-Richardson; DIC = 
ductal invasive carcinoma; LIC = lobular invasive carcinoma; ER = estrogen receptor; PR = progesterone receptorRadiation Oncology 2009, 4:12 http://www.ro-journal.com/content/4/1/12
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Table 4: Analysis of demographic, clinical, histological, molecular and therapeutic characteristics of patients treated with mastectomy 
and breast conservative therapy (BCT) (test Pearson Khi2)
Patients characteristics Mastectomy [n = 205] No (%) BCT [n = 39] No (%) p value
Age
<40 48 (23.4%) 6 (15.4%) 0.268
≥40 157 (76.6%) 33 (84.6%)
Menopausal status
No 129 (67.5%) 23 (63.9%) 0.669
Yes 62 (32.5%) 13 (36.1%)
Side
Right 48 (43.6%) 71 (53%) 0.146
Left 62 (56.4%) 63 (47%)
Histology
DIC 183 (91.1%) 36 (100%) 0.062
LIC 18 (9%) 0
SBR
I 13 (6.6%) 4 (10.5%) 0.53
II 130 (65.7%) 26 (68.4%)
III 55 (27.8%) 8 (21.1%)
Hormone receptors
ER
Positive 120 (60.3%) 28 (71.8%) 0.877
Negative 79 (39.7%) 11 (28.2%)
PR
Positive 61 (57.5%) 23 (59%) 0.877
Negative 45 (42.5%) 16 (41%)
Tumour
pT1 25 (12.4%) 10 (25.6%) 0.003
pT2 111 (55.2%) 27 (69.2%)
pT3 55 (27.4%) 2 (5.1%)
pT4 10 (5%) 0
pN, axillary
pN0 49 (23.9%) 11 (28.2%) 0.285
pN1 57 (27.8%) 15 (38.5%)
pN2 63 (30.7%) 10 (25.6%)
pN3 36 (17.6%) 3 (7.7%)
Protocol
Anthracycline 89 (43.4%) 21 (53.8%) 0.23
CMF 116 (56.6%) 18 (46.2%)
Breast/thoracic wall irradiation
Yes 194 (94.6%) 39 (100%) 0.139
No 11 (5.4%) 0
Prophylactic supraclavicular fossa radiotherapy
Yes 193 (94.1%) 38 (97.4%) 0.402
No 12 (5.9%) 1 (2.6%)
Internal mammary radiotherapy
Yes 195 (94.1%) 38 (97.4%) 0.523
No 10 (5.9%) 1 (2.6%)
Axillary radiotherapy
Yes 42 (20.5%) 7 (17.9%) 0.717
No 163 (79.5%) 32 (82.1%)
SBR = Scarf-Bloom-Richardson; DIC = ductal invasive carcinoma; LIC = lobular invasive carcinoma; ER = estrogen receptor; PR = progesterone receptorRadiation Oncology 2009, 4:12 http://www.ro-journal.com/content/4/1/12
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trial, 716 early breast cancers patients were treated by BCT
and randomised into tow groups (ACROSEIN study) [24].
In the first group, the patients were treated by the FNC
protocol (5-fluoro-uracil 500 mg/m2, mitoxantrone 12
mg/m2 and cyclophosphamide 500 mg/m2) with con-
comitant radiotherapy. In the second group, the patients
were treated by the FNC protocol followed by radiother-
apy. The results showed no significant difference in both
treatments for the 5-years DFS, LRFS, metastatic free sur-
vival, and OS. The two other studies [25,26] compared
concurrent and sequential chemotherapy and radiother-
apy after surgery for a reduced number of patients. In
Italy, Arcangely et al [25] followed 206 patients that were
randomly assigned to concurrent or sequential treat-
ments. The two protocols were performed after quadran-
tectomy and axillary dissection for breast cancer with
adjuvant chemotherapy (cyclophosphamide, methotrex-
ate, and fluorouracil [CMF]). No significant differences
were found in 5-years breast recurrence-free, metastasis-
free, disease-free, and overall survival for the two groups
of patients. In the third trial, Rouessé et al [26] followed
638 patients with prior breast surgery and positive axillary
dissection (from which 416 were breast conservative sur-
gery) and were randomly assigned to receive concomitant
radiotherapy and chemotherapy (FNC protocol) or chem-
otherapy (fluorouracil, epirubicin, and cyclophospha-
mide protocol) followed by RT. No differences in 5-years
disease-free and overall survival were observed in the two
treatment groups. Nevertheless, in the ACROSEIN study
the authors identified a significant decrease in the risk of
loco-regional recurrence by 39% with concurrent radio-
therapy and chemotherapy for node-positive patients.
Rouessé et al [26] showed that concurrent treatment has a
significantly better locoregional control in node-positive
breast cancer after conservative surgery. In our study we
found very good loco-regional control of the disease with
only one loco-regional recurrence in the anthracycline
goup and 8 in CMF group (p = 0.033). The main limita-
tion of the tree European trials was the use of CMF proto-
col and FNC protocol without the use of anthracyclines
and taxanes in the chemotherapy treatment. To our
knowledge, our study is the first investigation which tests
the efficacy and tolerability of the concomitant associa-
tion of anthracycline regimen with radiotherapy. Our
results confirm the superiority of this treatment to CMF
regimen in term of local control. Anthracycline adminis-
tered after RT showed a high incidence of severe skin der-
matitis and oesophagitis, as reported by Recht et al [17].
In contrary to mitoxantrone, the anthracycline chemo-
therapy induces free-radical production that may potenti-
ate normal tissue reactions. In ACROSEIN study, acute
loco regional toxicities were moderate in the concomitant
arm. Rouessé et al [26] presented more frequent grade 2
skin toxicities in the concomitant arm, and more sub clin-
ical left ventricular ejection fraction events at 1 year (p =
0.02). In our study we showed more haematological tox-
icity when the treatment is based on anthracycline with
significantly more grade II-III anaemia (13.9% vs 6.7%;
Khi2 test p = 0.009). Grade III-IV neutropenia (9.3% vs
6.2%) and thrombopenia (0.9% vs 0.8%) were equally
more frequent in anthracycline group but the differences
were not significant. The lack of cardiac toxicity evalua-
tion constitutes the main limitation of our retrospective
study. Other limitations were the lack of skin and pulmo-
nary toxicities evaluations. However, we can conclude
that there was no clinical cardiac toxicity in the two
groups and only 4.5% of the patients had poor cosmetic
results in the anthracycline group versus 0% in the CMF
group (Khi2 test: p = 0.039).
Conclusion
Concurrent chemo-radiotherapy is a valuable treatment
protocol which shows promising results with good toler-
ability in non operable and recurrent breast cancer.
In early breast cancer, the previous published studies
failed to show superiority of concurrent chemo-radiother-
apy in term of survival.
From the present five years retrospective investigation we
showed a similarity of the concurrent chemo-radiother-
apy treatment results in DFS and OS and we identified a
very good loco-regional control when this treatment was
based on anthracycline.
Waiting for the results of ongoing research the standard of
care is the use adjuvant chemotherapy prior to radiother-
apy.
Table 5: Haematological toxicity
Toxicity Group A No (%) Group B No (%)  p value
Anemia
Grade I 35 (32.4%) 25 (19.2%) 0.009
Grade II 13 (12%) 7 (5.4%)
Grade III 2 (1.9%) 1 (1.3%)
Grade IV 0
Neutropenia
Grade I 13 (12%) 15 (11.5%) 0.4
Grade II 27 (25%) 26 (20%)
Grade III 8 (7.4%) 8 (6.2%)
Grade IV 2 (1.9%) 0
Thrombopenia
Grade I 2 (1.9%) 2 (1.5%) 0.341
Grade II 2 (1.9%) 0
Grade III 1 (0.9%) 0
Grade IV 0 1 (0.8%)Radiation Oncology 2009, 4:12 http://www.ro-journal.com/content/4/1/12
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Loco-regional-Free Survival (LRFS) Figure 1
Loco-regional-Free Survival (LRFS): the delay of LRFS was calculated by the date of surgery until the date of revealing of 
a loco-regional recurrence or until the date of death, or until the date of last news. The median follow-up, the rate of LRFS in 
five years, and the number of patients censored were presented. Group A (anthracycline): N = 110 (1 events, 109 censored); 
Group B (CMF): N = 134 (8 events, 126 censored); Survival probability at five years: 98.6% in group A vs 94% in group B; Log-
rank test: p = 0.033.
Disease-Free Survival (DFS) Figure 2
Disease-Free Survival (DFS): the delay of DFS was calculated by the date of surgery until the date of revealing of a progress 
or until the date of death, or until the date of last news. The median follow-up, the rate of disease free survival in five years, and 
the number of patients censored were presented. Group A (anthracycline): N = 110 (21 events, 89 censored); Group B (CMF): 
N = 134 (36 events, 98 censored); Survival probability at five years: 80.4% in group A vs 76.4% in group B; Log-rank test: p = 
0.136.Radiation Oncology 2009, 4:12 http://www.ro-journal.com/content/4/1/12
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Overall survival (OS) Figure 3
Overall survival (OS): the delay of OS was calculated by the date of histological diagnosis until the death or until the date of 
last news. The median follow-up, the rate of overall survival in five years, and the number of patients censored were presented. 
Group A (anthracycline): N = 110 (19 events, 91 censored); Group B (CMF): N = 134 (29 events, 105 censored); Survival 
probability at five years: 82.5% in group A vs 81.1% in group B; Log-rank test: p = 0.428.
Overall survival (OS) Figure 4
Overall survival (OS): difference between the three anthracycline sub-groups: AC60, FEC75, and FAC50; Log-rank test: p = 
0.982.Radiation Oncology 2009, 4:12 http://www.ro-journal.com/content/4/1/12
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Disease-Free Survival (DFS) Figure 5
Disease-Free Survival (DFS): mastectomy compared to breast conservative therapy; Log-rank test: p = 0.288.
Overall survival (OS) Figure 6
Overall survival (OS): mastectomy compared to breast conservative therapy; Log-rank test: p = 0.173.Radiation Oncology 2009, 4:12 http://www.ro-journal.com/content/4/1/12
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Abbreviations
CMF: cyclophosphamide 500 mg/m2, methotrexate 60
mg/m2, and 5-fluorouracil 500 mg/m2; DFS: disease free
survival; OS: overall survival; LRFS: loco-regional recur-
rence free survival; AC60: doxorubicin 60 mg/m2 and
cyclophosphamide 600 mg/m2; FEC75: 5-fluorouracile
500 mg/m2, epirubicin 75 mg/m2, and cyclophospha-
mide 500 mg/m2; FAC50: 5-fluorouracile 500 mg/m2,
doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/
m2; BCT: breast conservative therapy; LVFE: left ventricu-
lar fraction ejection. FNC: 5-fluoro-uracil 500 mg/m2,
mitoxantrone 12 mg/m2 and cyclophosphamide 500 mg/
m2.
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